

FIG. 1









Bone marrow	Immature B cell		BAFF-R	Blood BM, spleen		BAFF-R	Lymph node				Bone marrow LN, MALT	Multiple myeloma
							Naive	GC	Memory	Plasmablast		
			BAFF-R			BAFF-R	BAFF-R	BAFF-R	BAFF-R	BCMA	BCMA	BCMA
			BAFF-R			BAFF-R	BAFF-R	BAFF-R	BAFF-R	BCMA	BCMA	BCMA
			BAFF-R			BAFF-R	BAFF-R	BAFF-R	BAFF-R	BCMA	BCMA	BCMA
			BAFF-R			BAFF-R	BAFF-R	BAFF-R	BAFF-R	BCMA	BCMA	BCMA

FIG. 2A




FIG. 2B




FIG. 3





FIG. 4



6/56

FIG. 5A

Subject Id	D28			D56			D184			D365		
	10 ⁻⁴	10 ⁻⁵	10 ⁻⁶	10 ⁻⁴	10 ⁻⁵	10 ⁻⁶	10 ⁻⁴	10 ⁻⁵	10 ⁻⁶	10 ⁻⁴	10 ⁻⁵	10 ⁻⁶
Subject Id												
L28US10002001		F.										
L28US10002002	NGS-	NGS-/F.	NGS+				NGS-	NGS-/F.	Indet.	NGS-	NGS-	NGS-
L28US10001002	NGS-	Indet.	Indet.									
L28US10001003	NGS-	Indet.	Indet.									
L28US10002004	Sample not collected											
L28US10002003	NGS-	NGS-/F.	NGS-				NGS-	NGS-/F.	Indet.			
L28US10002005	Cal. Fail.	F.					Sent	Sent	Sent			
L28US10008001	Cal. Fail.											
L28US10003001	NGS-	NGS-/F.	NGS-									
L28US10001005	Cal. Fail.											
L28US10002007	NGS-	NGS-/F.	NGS-									
L28US10001006	NGS-	NGS-	Indet.									
L28US10002008	NGS-	NGS-/F.	NGS-									
L28US10008002	Cal. Fail.											
L28US10002009	NGS-	NGS-/F.	NGS-		/F.							
L28US10003004	NGS-	NGS-	Indet.	NGS-	NGS-	NGS-						
L28US10001008	NGS-	NGS-	Indet.									
L28US10002011	NGS-	NGS-/F.	NGS-									
L28US10002006	NGS-	NGS-/F.	NGS-									
L28US10002012	NGS-	NGS-/F.	Indet.									

F = Flow cytometry
NGS = ClonoSeq

XXX = negative
XXX = positive
Indet. = Indeterminate

FIG. 5B

Subject Id	D28				D56				D184				D365			
	10 ⁻⁴	10 ⁻⁵	10 ⁻⁶		10 ⁻⁴	10 ⁻⁵	10 ⁻⁶		10 ⁻⁴	10 ⁻⁵	10 ⁻⁶		10 ⁻⁴	10 ⁻⁵	10 ⁻⁶	
L28US10001007	Sent	Sent /F-	Sent													
L28US10001010	NGS-	Indet.	Indet.													
L28US10002013	NGS-	NGS-/F-	NGS-													
L28US10002014		/F-				/F-										
L28US10002015	NGS-	NGS-	NGS-													
L28US10003006	Sent	Sent	Sent		NGS-	NGS-	NGS-									
L28US10003010	NGS-	Indet.	Indet.													
L28US10004001	NGS-	NGS-	Indet.													
L28US10008004	NGS-	NGS-	Indet.													
L28US10008005	NGS-	NGS-	NGS-													

F = Flow cytometry
NGS = ClonoSeq

XXX = negative
XXX = positive
Indet. = Indeterminate

FIG. 6

Translational research for CAR-T cell therapy (MMY2001)




FIG. 7




FIG. 8A





FIG. 8B



12/56



FIG. 8C

FIG. 9A



14/56


FIG. 9B

FIG. 10A





FIG. 10B



16/56


FIG. 11A

FIG. 11B




FIG. 11D




FIG. 11C




FIG. 12




FIG. 13A




FIG. 13B





FIG. 14A



23/56


FIG. 14B

FIG. 15




FIG. 16A




FIG. 16B




FIG. 16C




FIG. 17




FIG. 18

	CD3+ CAR+ CD4- CD8+ CCR7+ CD45RO- CD95- lymphocytes
	CD3+ CAR+ CD4- CD8+ CCR7+ CD45RO- CD95+ lymphocytes
	CD3+ CAR+ CD4- CD8+ CCR7+ CD45RO+ lymphocytes
	CD3+ CAR+ CD4- CD8+ CCR7- CD45RO+ lymphocytes
	CD3+ CAR+ CD4- CD8+ CCR7- CD45RO- lymphocytes

FIG. 19





FIG. 20A



30/56

FIG. 20B




FIG. 20C




FIG. 20D

LCAR-B38M




FIG. 21A




FIG. 21B




FIG. 21C




FIG. 22




FIG. 23




FIG. 24





FIG. 25



40/56




FIG. 26A





FIG. 26B

FIG. 27



42/56


**FIG. 28**

FIG. 29




FIG. 30




FIG. 31




FIG. 32




FIG. 33

LCAR-B38M Exhibits Variable Expansion and Persistence




FIG. 34




FIG. 35




FIG. 36

LCAR-B38M: Preferential Expansion of CAR+ CD8 T Cells in Blood and Bone Marrow




FIG. 37




FIG. 38

LCAR-B38M Exhibits Preferential Expansion of CD8 Central Memory T Cells





FIG. 39




54/56

FIG. 40

Conclusions for LCAR-B38M
▪ Post-infusion expansion of LCAR-B38M CAR-T cells (C_{max}) is highly variable and consistently peaks (T_{max}) around day 10-14 ▪ In 18/28 patients, the number of CAR+ T cells/μl are <LOQ (2 cells/μl) at 3 months of follow-up ▪ Best responses are independent of CD3 CAR-T peak expansion and persistence in the periphery at the time of data cut-off ▪ Best responses are independent of level of BCMA expression in MM cells ▪ LCAR-B38M is a differentiated CAR-t cell therapy that is highly active at a relatively low dose, potentially related to a preferential and consistent <i>in vivo</i> expansion of CAR+ CD8 T cells displaying a central memory phenotype.

FIG. 41



56/56

FIG. 42